BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	0.95
Equity-to-Asset	0.74
Debt-to-Equity	0.22
Debt-to-EBITDA	3.05
Interest Coverage	10.68
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.91	Distress Grey Safe
Beneish M-Score	-2.45	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	9.2
	3-Year EBITDA Growth Rate	54.8
	3-Year EPS without NRI Growth Rate	-21.6
	3-Year Book Growth Rate	5.1
	Future 3-5Y EPS without NRI Growth Rate	43.9
	Future 3-5Y Total Revenue Growth Rate	15.93

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	16
	9-Day RSI	26.01
	14-Day RSI	32.59
	6-1 Month Momentum %	6.54
	12-1 Month Momentum %	-2.75

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.74
	Quick Ratio	1.7
	Cash Ratio	0.96
	Days Inventory	735.25
	Days Sales Outstanding	90.13
	Days Payable	206.4

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.2
	Shareholder Yield %	-0.02

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	79.23
	Operating Margin %	7.17
	Net Margin %	8.31
	FCF Margin %	6.67
	ROE %	4.22
	ROA %	3.07
	ROIC %	2.99
	ROC (Joel Greenblatt) %	11.19
	ROCE %	4.4
	Years of Profitability over Past 10-Year	3

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	76.76
	Forward PE Ratio	31.06
	PE Ratio without NRI	43.05
	PS Ratio	6.43
	PB Ratio	3.07
	Price-to-Tangible-Book	3.31
	Price-to-Free-Cash-Flow	97.08
	Price-to-Operating-Cash-Flow	56.6
	EV-to-EBIT	60.53
	EV-to-Forward-EBIT	46.42
	EV-to-EBITDA	42.79
	EV-to-Forward-EBITDA	33.59
	EV-to-Revenue	6.22
	EV-to-Forward-Revenue	5.68
	EV-to-FCF	95.86
	Price-to-Projected-FCF	3.93
	Price-to-Median-PS-Value	0.59
	Price-to-Graham-Number	2.49
	Price-to-Net-Current-Asset-Value	12.82
	Earnings Yield (Greenblatt) %	1.65
	FCF Yield %	1.07

GF Value: €96.29

STU:BM8

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with BM8. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.